LONDON (Alliance News) - Midatech Pharma PLC on Thursday said it achieved positive dosing data for its OpsiSporin uveitis programme, and is on track for an investigational new drug application in the second half of 2017.
The company said it had seen positive data from its programme for OpsiSporin in the treatment for non-infective uveitis, which is an inflammatory disorder of the eye that can result in significant vision loss.
Midatech Pharma said that, in a recent study to evaluate the efficacy of MTD202 in a preclinical model of experimental autoimmune uveitis, a strong dose response profile was demonstrated.
"This is a significant milestone in our own R&D pipeline and we are on track to advance this programme into the clinic. With the product attributes of being steroid and immunosuppressant sparing there is now full justification to progress the programme through to commercial development so we are now preparing for an IND in 2017," said Midatech Chief Executive Officer Jim Phillips in a statement.
"We see OpsiSporin as another important programme in our rapidly evolving pipeline," Phillips added.
Shares in MidaTech were up 7.4% at 159.00 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
